MetaVia (MTVA) Change in Accured Expenses (2015 - 2025)
MetaVia's (MTVA) quarterly Change in Accured Expenses came in at -$1.2 million in Q4 2025, up 65.62% YoY from -$727566.8 in Q4 2024, and down 657.86% on a QoQ basis from -$159000.0 in Q3 2025.
MetaVia (MTVA) Change in Accured Expenses (2015 - 2025) Analysis & Trends
MetaVia (MTVA) has 11 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 65.62% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $431000.0 (up 193.49% YoY) and the FY2025 annual result came in at $431000.0, up 193.49% from the prior year.
- Change in Accured Expenses slipped to -$1.2 million in Q4 2025, from -$159000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.8 million in Q4 2023 to a low of -$3.5 million in Q4 2024.
- A 5-year average of $166800.0 and a median of -$2000.0 in 2021 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 1663.3% — and 2024, when it tumbled 440.88%.
- Tracing MTVA's Change in Accured Expenses over 5 years: stood at $374000.0 in 2021, then plunged by 151.07% to -$191000.0 in 2022, then soared by 1568.06% to $2.8 million in 2023, then sank by 225.0% to -$3.5 million in 2024, then surged by 65.62% to -$1.2 million in 2025.
- The last three Change in Accured Expenses figures came in at -$1.2 million (Q4 2025), -$159000.0 (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.21 Mn |
| Dec 31, 2025 | -1.21 Mn |
| Sep 30, 2025 | -159,000.00 |
| Sep 30, 2025 | -159,000.00 |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 348,000.00 |
| Mar 31, 2025 | 348,000.00 |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | -467,000.00 |
| Mar 31, 2024 | -467,000.00 |
| Dec 31, 2023 | 2.80 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | -431,000.00 |
| Sep 30, 2023 | -431,000.00 |